by Thomas Lethenborg | Jun 21, 2016 | News, Press releases
Copenhagen, Denmark – 21 June 2016. Monsenso, a Copenhagen-based technology company, announced today that the NHS Foundation Trust of Central Northwest London (CNWL) will implement the Monsenso mobile health (mHealth) solution to support the treatment of young patients suffering from schizophrenia.
The pilot, which will run from July to December, will be implemented amongst young patients aged 18 to 24, across Kensington, Chelsea, Westminster, Milton Keynes, and Hillingdon. It will be the first step prior to rolling out the solution more widely and fully integrating it with TTP SystmOne enabling clinicians to access all patient data from one place.
The objective of the pilot is to evaluate the clinical and economic benefits of using the Monsenso solution such as reducing the number of psychiatric readmissions and using the latest technology to collect and analyse patient data.
With the help of the Monsenso mHealth solution, clinicians will be able to identify the triggers and early warning signs of the young patients and intervene at an early stage to avoid emergency situations. The clinical web portal provides clinicians with an insight into the correlation between a patient’s behavioural patterns and the illness enabling them to provide a more informed and better treatment to a larger number of patients.
Thomas Lethenborg, CEO at Monsenso ApS, said “CNWL aims to offer its patients high-quality treatment with the latest technology available. With the implementation of the Monsenso mHealth solution, clinicians will be able to access a patient’s historical aggregated data, which will help them offer a better treatment based on evidence.”
Dr Pramod Prabhakaran, Divisional Medical Director of CNWL, said “We are working closely with our service users, partners, and stakeholders to be more responsive towards people’s needs. The implementation of the Monsenso mHealth solution is part of a wider service redesign to improve our community mental health services across North West London.”
For additional information about Monsenso contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
For additional information about CNWL contact:
Mike Waddington
Communications Director
CNWL
+44 77 40 42 28 73
mikewaddington@nhs.net
About CNWL
Central and North West London NHS Foundation Trust is one of the largest trusts in the UK, caring for people with a wide range of physical and mental health needs. We provide a wide range of services to treat people with a variety of health needs. In broad terms, these include common physical health problems, long-term conditions, mental health, learning disabilities, eating disorders, addictions and sexual health. We are here to provide support for people through every stage of life. The majority of our services are provided in the community, which means treating people in their homes or from clinics close to home. Where community care is not possible we offer a number of facilities to treat people in the hospital or residential environments. We also provide healthcare in prisons in London and the surrounding areas. We are committed to providing services that meet the needs of the people who use them, and we actively encourage involvement from local people who can help make a difference.[/vc_column_text][vc_column_text]You can download this article as PDF in English and Danish
by Thomas Lethenborg | Apr 14, 2016 | News, Press releases
Copenhagen, Denmark – 14 April 2016. Monsenso ApS announced today that Thomas Lethenborg, CEO of Monsenso participated as a guest speaker at WHO mental health meeting. The two-day event titled “Out of the Shadows: Making Mental Health a Global Development Priority” was co-hosted by the World Bank Group and World Health Organization (WHO).
The WHO mental health meeting, which took place in Washington D.C. on April 13-14, aimed to include mental health as a priority in the global development agenda. Additionally, Thomas Lethenborg will participate in a panel discussion titled “Leveraging New Technologies for Improving Access to Care and Designing New Interventions.”
Mental health has received inadequate attention by policy makers and society in general. However, mental and behavioural disorders impose an enormous illness burden in addition to being very costly to country economies. According to WHO, in 2010 the global cost of mental disorders was estimated to be approximately US$2.5 trillion and by 2030 that figure is projected to go up by 140%, to US$6.0 trillion.
It has been estimated that the vast majority of low and middle-income countries allocate less than 1% of their health budgets to mental health, making them ill-equipped to deal with this “invisible” and often-ignored challenge.
With regards to his participation at the event, Thomas Lethenborg, said: “Due to these existing challenges, mental health must become a priority in the global health agenda and mHealth technology has the potential to bring better treatment to more people at lower cost.”
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com[/vc_column_text][vc_column_text]You can download this article as PDF in English and Danish
by Thomas Lethenborg | Mar 15, 2016 | News, Press releases
Copenhagen, Denmark – 15 March 2016. Monsenso ApS, an innovation leader in mobile health (mHealth) solutions for mental health, announced today the development of a triple-loop mHealth solution that enables information-sharing between patients, carers and clinicians to support the treatment of 1,000 individuals suffering from schizophrenia.
The mHealth solution, designed and developed by Monsenso, will provide healthcare professionals and family caregivers with access to the patient’s information.
Patients will be encouraged by their care providers to download the Monsenso smartphone app that will allow them to invite their care providers and family caregivers to access their data.
The smartphone app will be used to fill in routine self-assessments that reveal their current state of mind, and to collect sensor data. It can also be used as a self-management tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms.
Once invited by the patient, a family caregiver will be able to use a similar app to access the patient’s aggregated data and fill in the routine assessments evaluating the patient’s state of mind.
Healthcare professionals will use a web portal where they can access all the data collected by the patients’ and caregivers’ smartphones anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.
In relation to the development of the triple-loop solution, Thomas Lethenborg, CEO at Monsenso, commented. “We are approaching treatment in a way that has never been done before. There are currently a few mHealth solutions that offer a double-loop treatment model for patients and care providers. However, Monsenso will be the first company ever to develop and implement an mHealth platform that involves patients, care providers and family caregivers in the treatment of a mental illness. The caregiver module, which is currently under development, will be ready to be rolled out in Q3 2016, and will initially be used for two years.”
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
You can download this article as PDF in English and Danish
by Thomas Lethenborg | Feb 23, 2016 | News, Press releases
Copenhagen, Denmark – 23 February 2016. Monsenso, a Copenhagen-based technology company, announced today that the Zealand Healthcare Region in Denmark will use the Monsenso mHealth solution for remote patient monitoring of patients with Borderline Personality Disorder (BPD).
The objective of the pilot study is to identify and track the triggers and early warning signs of patients with borderline, as well as to gather clinical evidence with the Monsenso mHealth solution.
The pilot study will be done in collaboration with the Produktion, Forskning and Innovation Centre of the Zealand Healthcare Region in Denmark. This branch focuses on identifying pioneering solutions that have the potential to improve the productivity of hospitals and the quality of life of its patients.
Thomas Lethenborg, CEO at Monsenso ApS, said that the Zealand Healthcare Region will conduct a 20-week pilot study of 30 patients starting in March.
“The Innovation Centre of the Zealand Healthcare Region in Denmark aims to offer its patients high-quality treatment with the latest technology available. With the implementation of the Monsenso mHealth solution, clinicians will be able to access a patient’s historical aggregated data, which will help them offer a better treatment based on evidence,” said Mr Lethenborg.
Jesper Lackman, Project Manager at The Produktion, Forskning and Innovation Centre, said the pilot study would allow them to investigate the benefits of the mHealth solution to improve patient engagement.
“The Produktion, Forskning and Innovation Centre has a strong commitment towards providing patient-centred care. We are continuously looking to improve our patients’ experience and this technology will help us learn more about our patients and their behavioural patterns. Our aim is to use this technology to support the treatment we currently provide to our patients,” said Mr Lackman.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
Jesper Lakman
Innovation Facilitator
PFI – Production, Science & Innovation
+45 8171 2900
jelak@Sundhedsinnovation.com
You can download this article as PDF in English
by Thomas Lethenborg | Feb 16, 2016 | News, Press releases
Copenhagen, Denmark – 16 February 2016. Monsenso ApS, a technology leader in mobile health solutions for mental health, today announced that last Friday, its mHealth solution received a CE Mark. The double-loop treatment platform that supports the treatment of major psychiatric disorders received a Class 1 Medical Device Certification under the EU Medical Devices Directive.
The certification has been obtained due to the support received from the Market Development Fund (MMF) in May 2015, which granted 2.9 million to DKK for Monsenso and its partners to obtain the necessary certifications for the solution to be ready for an international launch.
With regards to obtaining the CE Marking Certification, Thomas Lethenborg, CEO at Monsenso, commented “Obtaining this certification is an important milestone for Monsenso since our mHealth solution is based on solid research and has already been clinically validated. Our objective with this certification is to be regarded as a medical application rather than just another app.”
A CE Marking Certification guarantees that a manufacturer’s product meets the essential requirements of all relevant European Medical Device Directives.
“Holding a CE Marking Certification and offering a high level of data security is a demand from our customers across the globe. Therefore, it is important that Monsenso can distinguish itself from all other apps with no clinical evidence or inadequate security measures” added Mr. Lethenborg.
The next step for Monsenso is to obtain the ISO 27001 Data Security Certification, the ISO 13485 Certification, and to become HIPAA and FDA compliant, which is also part of the support granted by the MMF funding.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
You can download this article as PDF in English and Danish
by Thomas Lethenborg | Feb 9, 2016 | News, Press releases
Copenhagen, Denmark – 9 February 2016. Monsenso ApS, a Copenhagen-based technology company, has been granted 3.065 million DKK by the Innovation Fund to develop further develop their mHealth solution that aims to reduce hospital readmissions of patients with depression and bipolar disorder.
The RADMIS research project, which has been granted a budget of 10.1 million DKK by the Innovation Fund, is being done in collaboration with the Mental Health Services of the Capital Region of Denmark (RHP) and the Danish Technical University (DTU).
Depression and bipolar disorder are the leading cause of disability worldwide, imposing a very high burden for society in terms of cost, lost productivity, and mortality. Besides, patients with affective disorders are hospitalized more frequently than any other patient group. The treatment of depression and bipolar disorder includes medication, psycho-education, and Cognitive Behavioral Therapy (CBT).
The RADMIS research project aims to establish clinical evidence that the Monsenso mHealth solution can reduce the number of hospital readmissions of patients with depression and bipolar disorder. It also seeks to decrease the symptoms and improve the quality of life of outpatients with depression or bipolar disorder receiving smartphone-based CBT.
Since smartphones are equipped with powerful sensing, computation and communication capabilities, they provide a unique platform to monitor and treat patients with depression and bipolar disorder. Moreover, smartphones also provide a rich multi-media and communication platform for Ecological Momentary Intervention (EMI) enabling patients to receive context-aware treatment in real-time, including medication reminders and CBT.
The innovation goals of the RADMIS research project are to:
- Research, design, and develop an intelligent smartphone-based monitoring and treatment platform for affective disorders
- Provide clinical evidence to reduce the number and duration of hospital re-admissions of patients with depression and bipolar disorder using smartphone-based treatment
- Provide clinical evidence that smartphone-based CBT improves the health outcomes for patients with depression and bipolar disorder
With regards to the new capabilities that will be added to the Monsenso mHealth solution, Thomas Lethenborg, CEO at Monsenso commented, “This intelligent smartphone-based monitoring and treatment platform for depression and bipolar disorders is the first of its kind; there are no similar solutions available on the market.”
“Once the clinical trial is completed, we will have the necessary evidence to prove that smartphone-based CBT helps reduce hospital readmissions of psychiatric patients. Besides, it allows health care systems to reach out to the 75% of the population in Europe who need treatment, but remain untreated,” added Mr. Lethenborg.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.comYou can download this article as PDF in English and Danish
